Statins market seen reaching $21.2 billion by 2033

By AI, Created 9:36 AM UTC, June 03, 2026, /AGP/ – The global statins market is projected to grow from $17.1 billion in 2026 to $21.2 billion by 2033 as cardiovascular disease, obesity and diabetes drive demand for cholesterol-lowering drugs. North America leads today, while Asia Pacific is emerging as a growth market on rising healthcare access and preventive screening.

Why it matters: - Statins remain a core treatment for lowering cholesterol and reducing cardiovascular risk as heart disease rates climb worldwide. - The market’s growth reflects broader adoption of preventive care, routine screening and earlier treatment of high-risk patients. - Wider generic availability is expanding access in emerging markets.

What happened: - The global statins market is projected to rise from US$ 17.1 billion in 2026 to US$ 21.2 billion by 2033. - The forecast implies a compound annual growth rate of 3.1% from 2026 through 2033. - Persistence Market Research identified rising high cholesterol, obesity, diabetes and other heart-related disorders as the main demand drivers. - Oral statin therapies continue to dominate because of convenience and strong clinical outcomes.

The details: - The market includes atorvastatin, rosuvastatin, simvastatin, pravastatin and other formulations. - Atorvastatin-based therapies are seeing strong demand because physicians favor them and they are effective at lowering cholesterol. - The market is segmented by product type, distribution channel and end user. - Hospitals, retail pharmacies, specialty clinics and online pharmacies are major end users. - Hospitals generate significant demand because of high patient volumes. - Retail pharmacies hold a strong share because they are easy to access and support prescription refills. - North America remains the leading regional market because of advanced healthcare infrastructure, high treatment access, rising cholesterol screening and favorable reimbursement systems. - Asia Pacific is emerging as a key growth region because healthcare access is expanding, lifestyles are changing and cardiovascular disease prevalence is increasing. - Rising healthcare investment and affordable medication availability are supporting Asia Pacific expansion.

Between the lines: - The market is growing even with pressure from generic competition and pricing cuts. - Side effects and long-term adherence remain barriers to uninterrupted treatment. - Combination therapies may become an important next growth avenue as companies look for ways to extend the category. - The competitive field includes Pfizer, AstraZeneca, Novartis, Merck, Teva, Sun Pharmaceutical, Lupin, Dr. Reddy’s, Viatris and Sanofi.

What’s next: - Preventive healthcare adoption and routine screening programs are likely to keep supporting demand for statins. - Expanding healthcare infrastructure in emerging economies should continue widening treatment access. - Combination therapy development may create additional market opportunities. - More information is available in the full report sample, custom report request and full report purchase page.